Search clinical trials for: inotuzumab ozogamicin rituximab cyclophosphamide vincristine prednisone

Total 617 results

Pfizer
UCB Pharma

Completed

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

Korea, Republic of, Canada, Belgium, Singapore, United States, Hong Kong, Japan, United Kingdom, France
Pfizer
UCB Pharma

Terminated

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular

Belgium, United States, Canada, Hong Kong, Korea, Republic of, Portugal, Spain, Poland, India, Argentina, Italy, Mexico, Russian Federation, South Africa
Pfizer

Completed

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Lymphoma, B-Cell

Japan
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, France, United Kingdom, Singapore, Korea, Republic of, Germany
M.D. Anderson Cancer Center
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

B-Cell Lymphoma

United States, Belgium, Korea, Republic of, Switzerland, France, Poland, Spain, Hong Kong, Australia, Germany, Italy, Netherlands, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

United States
Pfizer
UCB Pharma

Terminated

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Lymphoma, Non-Hodgkin

Canada, United States, Spain, France, Singapore, Taiwan, Japan, Ireland, Belgium, United Kingdom, Germany, Slovakia, Thailand, Croatia, Czechia, Russian Federation, India, Sweden, Poland, Bulgaria, Hungary, Lithuania, Mexico, Puerto Rico and more
University of Nebraska
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Hong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
Acrotech Biopharma Inc.
Axis Clinicals Limited

Unknown

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Hematologic Diseases
NCIC Clinical Trials Group

Completed

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

Canada
Weill Medical College of Cornell University
Genentech, Inc.; Biogen

Completed

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Immune Thrombocytopenic Purpura

United States
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Hoffmann-La Roche

Completed

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Italy, United Kingdom, Belgium, Brazil, Denmark, France, Peru, Colombia, Canada, Georgia, Singapore, Spain, Thailand, Australia, Germany, Mexico, Russian Federation, South Africa, Finland, Bosnia and Herzegovina, Bulgaria, Croatia, ... and more
Eli Lilly and Company

Completed

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Lymphoma

United States
Pusan National University Hospital

Unknown

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

Diffuse Large B-cell Lymphoma
Konkuk University Medical Center
Seoul St. Mary's Hospital

Completed

R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

Lymphoma

Korea, Republic of
University College, London
Pfizer; Cancer Research UK

Completed

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy (INCA)

Diffuse Large B Cell Lymphoma

United Kingdom
Children's Cancer Group, China
Xiangya Hospital of Central South University; Qilu Hospital of Shandong University and other collaborators

Active, not recruiting

BNHL-2015 for Children or Adolescents in China (BNHL-2015)

Mature B-cell Non-Hodgkin Lymphoma

China
Zeneus Pharma

Unknown

Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

Aggressive Non-Hodgkin's Lymphoma in the Elderly.

France, Germany, Spain, United Kingdom, Italy
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

Germany, Israel, Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia...

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Large B Cell Lymphoma

United States
Seagen Inc.

Terminated

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse, Large B-Cell, Lymphoma | Follicular Lymphoma, Grade 3b | Transformed Lymphoma / DLBCL

United States, Puerto Rico
Weill Medical College of Cornell University
Celgene

Completed

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

United States
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

Netherlands
Chipscreen Biosciences, Ltd.

Active, not recruiting

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (DEB)

Diffuse Large B-cell Lymphoma

China
Universität des Saarlandes

Completed

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Lymphoma
European Organisation for Research and Treatment...
NCIC Clinical Trials Group; Stichting Hemato-Oncologie voor Volwassenen Nederland and other collaborators

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Lymphoma

France, Netherlands, United Kingdom, Australia, Canada, Norway, Poland, Belgium, Italy, New Zealand, Denmark, Egypt, Hungary, Portugal, Slovakia, Slovenia, South Africa, Sweden
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Lymphoma

United States
German CLL Study Group

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Chronic Lymphocytic Leukemia

Germany
Amgen

Unknown

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
Roswell Park Cancer Institute
Pfizer

Withdrawn

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Blasts 5 Percent or More of Peripheral Blood White Cells | Lymphoblasts... and other conditions

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
Shanghai Public Health Clinical Center

Unknown

The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma

To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma
SWOG Cancer Research Network
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and...

Active, not recruiting

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma

United States
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

Germany, Switzerland
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma

Germany, Israel
Seagen Inc.

Terminated

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-cell, Diffuse | Lymphoma, B-cell

United States, Spain, Italy, Czechia, Poland
Ohio State University Comprehensive Cancer Center

Withdrawn

Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma

Lymphoma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Lymphoma

United States
Swiss Group for Clinical Cancer Research

Completed

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Leukemia

Switzerland
Joseph Tuscano
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Double-Expressor Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Lymphoma

Switzerland, Germany, Italy, Netherlands, Poland, Sweden, United Kingdom, France, Czechia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Swiss Group for Clinical Cancer Research

Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lymphoma

Switzerland, Italy

Search clinical trials for: inotuzumab ozogamicin rituximab cyclophosphamide vincristine prednisone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations